NCT07479407Not yet recruiting
Effect of Pre-operative Exercise Training on Cardiorespiratory Fitness in Patients With Locally Advanced Non-small Cell Lung Cancer Undergoing Induction Chemo-immunotherapy Followed by Surgery - a Randomized Controlled Study
Source: ClinicalTrials.gov · Last updated 18 Mar 2026
Brief summary (registry, in English)
The PREHAB study focuses on patients with locally advanced non-small cell lung cancer (NSCLC) undergoing neoadjuvant chemotherapy and/or immunotherapy prior to surgical resection. These systemic treatments frequently impair patients' physiological reserve, reduce physical fitness, and may occasionally lead to cancellation of surgery. Surgery itself carries a substantial risk of cardiorespiratory complications and long-term functional decline. The primary objective of this study is to determine whether a supervised exercise program, initiated concomitantly with systemic therapy and continued until surgery, can improve cardiorespiratory fitness, surgical tolerance, and postoperative outcomes. A total of 74 patients will be randomly assigned to one of two groups: an "intervention" group participating in three weekly sessions of supervised endurance and resistance training for 12 to 16 weeks under the guidance of a physiotherapist, and a "control" group receiving usual care without a structured exercise program. The primary endpoint will be peak oxygen uptake (VO₂peak). Secondary outcomes will include postoperative complication rates, length of hospital stay, pulmonary function, skeletal muscle mass, and quality of life. Intervention-related risks, primarily falls or overexertion, will be mitigated through professional supervision. This multicenter study, with recruitment scheduled to begin in 2026, is expected to provide robust evidence regarding the effectiveness of targeted exercise training in improving preoperative fitness and postoperative recovery in patients with locally advanced NSCLC.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 74 (estimated)
- First submitted
- 4 Mar 2026
- Start date
- Apr 2026
- Primary completion date
- Mar 2029
- Lead sponsor
- Hôpital du Valais
- Diseases
- Lung cancer
- NCT number
- NCT07479407
What you commit to
- Study type: Interventional
- Planned participants: 74
- From Apr 2026 to the primary completion date, Mar 2029
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Induction therapy already initiated.
Other
- Pregnancy (confirmed by a test if applicable).
- Inability to walk independently.
- Lack of decision-making capacity.
- Oxygen-dependency before the initiation of the induction protocol.
- No capacity for discernment.
- Does not speak French.
Who the study is looking for
- Age ≥18 years.
- Confirmed diagnosis of stage IIB, IIIA, IIIB or oligo-metastatic stage IV NSCLC.
- Planned induction therapy with either chemotherapy, immunotherapy or a combination of immuno-chemotherapy followed by an anatomical pulmonary resection.
- Absence of musculoskeletal conditions preventing safe physical exercise.
- Absence of any history of uncontrolled or unstable cardiac disease.
- Agreement to participate in the study by signing the study specific informed consent form.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hôpitaux universitaires de Genève Coordinator of this site? Confirm its status | Geneva | Switzerland | Unknown status |
| Centre Hospitalier Universitaire Vaudois Coordinator of this site? Confirm its status | Lausanne | Switzerland | Unknown status |
| Hôpital de Sion Coordinator of this site? Confirm its status | Sion | Switzerland | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.